NXP002 data to be presented at 2022 ERS Congress
5 July 2022
("Nuformix" or the "Company" or the "Group")
NXP002 data to be presented at the 2022 European Respiratory Society Congress
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that both of the abstracts submitted for presentation at the European Respiratory Society ("ERS") International Congress 2022 in Barcelona on September 4-6, on its lead asset NXP002, have been peer-reviewed and accepted for presentation. NXP002 is a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF").
Commenting, Dr Julian Gilbert, Non-executive Director of Nuformix, said: "We believe NXP002 offers tremendous potential as a novel inhaled treatment for IPF and potentially other fibrosing interstitial lung diseases ("ILDs"). The Company is progressing a pre-clinical programme to demonstrate how its proprietary new form of tranilast can down regulate fibrosis and inflammation following inhalation, whilst avoiding severe side effects, which are key issues in the treatment of IPF and other ILDs. We are therefore delighted that the abstracts describing our initial work have been accepted following peer review.
"The ERS is a leading international respiratory congress. It provides us the opportunity to share these positive data with the scientific and clinical communities and, very importantly, the congress is attended by all the major respiratory-focused pharmaceutical companies. Ultimately, we will be looking to license NXP002 and the congress offers us an important opportunity to present and introduce NXP002 to potential licensing partners."
Dr Julian Gilbert, Non-executive Director
Maddy Kennedy, Non-executive Director
Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)
+44 (0) 20 3650 3650
John Howes (Corporate Broking)
+44 (0) 20 3650 3652
IFC Advisory Limited
+44 (0) 20 3934 6630
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.